Disclosed herein are modified soluble -Klotho proteins and isolated fragments of wildtype soluble -Klotho protein. Also disclosed are pharmaceutical compositions including the modified soluble -Klotho proteins and/or isolated fragments of soluble -Klotho protein and methods of their use in treating a subject.

The present invention relates to a Lactobacillus strain having antimicrobial activity against Gardnerella vaginalis and Candida albicans, a culture medium of the strain, and a cell-free supernatant of the strain, and to an antimicrobial composition containing the same, a pharmaceutical composition for preventing or treating Gardnerella vaginalis infection or Candida albicans infection containing the same, a pharmaceutical composition for prevention or treatment of vaginitis containing the same, a health functional food for prevention or ameliorating of vaginitis containing the same, and a quasi-drug composition for prevention or amelioration of vaginitis containing the same. The Lactobacillus paracasei MG4272 strain in accordance with the present disclosure has excellent antimicrobial activity against Gardnerella vaginalis and Candida albicans, and has excellent acid resistance, bile resistance, autoaggregation ability and epithelial cell adhesion ability and is suitable for probiotics and thus may be used in various ways for the prevention or treatment of Gardnerella vaginalis infection, Candida albicans infection and vaginitis.

The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.

Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.

The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.

The present invention relates to a lactobacillus strain having antimicrobial activity against Gardnerella vaginalis and Candida albicans, a culture medium of the strain, and a cell-free supernatant of the strain, and to a antimicrobial composition containing the same, a pharmaceutical composition for preventing or treating Gardnerella vaginalis infection or Candida albicans infection containing the same, a pharmaceutical composition for prevention or treatment of vaginitis containing the same, a health functional food for prevention or ameliorating of vaginitis containing the same, and a quasi-drug composition for prevention or ameliorating of vaginitis containing the same. The Lactobacillus paracasei MG4272 strain in accordance with the present disclosure has excellent antimicrobial activity against Gardnerella vaginalis and Candida albicans, and has excellent acid resistance, bile resistance, autoaggregation ability and epithelial cell adhesion ability and is suitable for probiotics and thus may be used in various ways for the composition of prevention or treatment of Gardnerella vaginalis infection, Candida albicans infection and vaginitis.

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.

An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof specifically binds to an epitope of a Klotho polypeptide, optionally a folded Klotho or optionally with a dissociation constant (K.sub.D) of about 2 nM or less, as measured by competitive ELISA assay, methods of making and using to diagnose kidney diseases.

Recombinant Klotho proteins, nucleic acids encoding the same, cell lines and cultures expressing the same, and method of manufacturing and administering the same are disclosed. Proteins have at least 80% amino acid sequence identity to a portion of human alpha Klotho and preferably a solubility or half-life-extending feature such as glycosylation and/or fusion protein tag. Treatment protocols include determining Klotho levels in a subject, calculating a dosage of the protein sufficient to raise the Klotho level in the subject to a predetermined level, administering the dosage to the subject, determining a rate of protein decline in the subject following administration of the protein, calculating a time and/or amount of a subsequent dosage of the protein, and/or administering the subsequent dosage to the subject. Proteins and related treatments for addressing aging-associated and other conditions are disclosed.